Comparative Pharmacology
Head-to-head clinical analysis: KETOPROFEN versus NAPRELAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KETOPROFEN versus NAPRELAN.
KETOPROFEN vs NAPRELAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis; also inhibits leukotriene synthesis and has direct membrane-stabilizing effects.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, which mediates pain, inflammation, and fever.
Oral: 75 mg three times daily or 50 mg four times daily; maximum 300 mg/day. Intravenous: 100 mg every 12-24 hours, infused over 15-30 minutes.
750 mg to 1000 mg orally once daily, with or without food.
None Documented
None Documented
Terminal elimination half-life: 2-4 hours; clinical context: short half-life allows for quick drug clearance but requires frequent dosing; may be prolonged in elderly or renal impairment.
Clinical Note
moderateKetoprofen + Gatifloxacin
"Ketoprofen may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderateKetoprofen + Rosoxacin
"Ketoprofen may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderateKetoprofen + Levofloxacin
"Ketoprofen may increase the neuroexcitatory activities of Levofloxacin."
Clinical Note
moderateKetoprofen + Trovafloxacin
"Ketoprofen may increase the neuroexcitatory activities of Trovafloxacin."
Terminal elimination half-life: 10-20 hours; context: allows twice-daily or once-daily dosing for chronic pain or inflammation.
Renal: ~80% (60% as glucuronide conjugates, 20% as unchanged drug); Biliary/Fecal: ~20% via bile.
Renal: 50-60% as metabolites and conjugates; biliary/fecal: ~5%; remainder uncharacterized.
Category D/X
Category C
NSAID
NSAID